JP2022524337A - 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質 - Google Patents

腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質 Download PDF

Info

Publication number
JP2022524337A
JP2022524337A JP2021552717A JP2021552717A JP2022524337A JP 2022524337 A JP2022524337 A JP 2022524337A JP 2021552717 A JP2021552717 A JP 2021552717A JP 2021552717 A JP2021552717 A JP 2021552717A JP 2022524337 A JP2022524337 A JP 2022524337A
Authority
JP
Japan
Prior art keywords
domain
seq
variable
terminus
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021552717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524337A5 (enExample
Inventor
ビー ダブリッジ，ロバート
パンシャル，アナンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022524337A publication Critical patent/JP2022524337A/ja
Publication of JP2022524337A5 publication Critical patent/JP2022524337A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021552717A 2019-03-05 2020-03-05 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質 Ceased JP2022524337A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962814159P 2019-03-05 2019-03-05
US201962814210P 2019-03-05 2019-03-05
US62/814,210 2019-03-05
US62/814,159 2019-03-05
US201962814744P 2019-03-06 2019-03-06
US62/814,744 2019-03-06
US201962826523P 2019-03-29 2019-03-29
US62/826,523 2019-03-29
PCT/US2020/021276 WO2020181145A1 (en) 2019-03-05 2020-03-05 Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens

Publications (2)

Publication Number Publication Date
JP2022524337A true JP2022524337A (ja) 2022-05-02
JP2022524337A5 JP2022524337A5 (enExample) 2023-03-13

Family

ID=70058513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552717A Ceased JP2022524337A (ja) 2019-03-05 2020-03-05 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質

Country Status (7)

Country Link
US (1) US20220144949A1 (enExample)
EP (1) EP3934761A1 (enExample)
JP (1) JP2022524337A (enExample)
CN (1) CN114173876A (enExample)
AU (1) AU2020231391A1 (enExample)
CA (1) CA3132651A1 (enExample)
WO (1) WO2020181145A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
EP4416185A4 (en) * 2021-10-15 2025-09-03 Harpoon Therapeutics Inc CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES
WO2026038047A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof
WO2026038048A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof
WO2026038050A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529853A (ja) * 2014-09-25 2017-10-12 アムジエン・インコーポレーテツド プロテアーゼにより活性化可能な二重特異性タンパク質
WO2019051122A2 (en) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS
WO2019051102A2 (en) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
DE10231109A1 (de) 2002-07-10 2004-01-22 Daimlerchrysler Ag Abgasturbine
HUE054131T2 (hu) * 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
AU2017229687A1 (en) 2016-03-08 2018-09-20 Takeda Pharmaceutical Company Limited Inducible binding proteins and methods of use
WO2018160754A2 (en) * 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
MX2020012217A (es) * 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
EP3833444A1 (en) * 2018-08-09 2021-06-16 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529853A (ja) * 2014-09-25 2017-10-12 アムジエン・インコーポレーテツド プロテアーゼにより活性化可能な二重特異性タンパク質
WO2019051122A2 (en) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS
WO2019051102A2 (en) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins

Also Published As

Publication number Publication date
CN114173876A (zh) 2022-03-11
WO2020181145A1 (en) 2020-09-10
AU2020231391A1 (en) 2021-10-28
EP3934761A1 (en) 2022-01-12
US20220144949A1 (en) 2022-05-12
CA3132651A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
US12478673B2 (en) Constrained conditionally activated binding proteins
US20220144949A1 (en) CONDITIONALLY ACTIVATED BINDING PROTEINS CONTAINING Fc REGIONS AND MOIETIES TARGETING TUMOR ANTIGENS
JP2020534811A (ja) Ｆｃ領域を含有する条件的に活性化された結合部分
CN114390938B (zh) 受约束的条件性活化的结合蛋白
US20210309756A1 (en) Coexpression and purification method of conditionally activated binding proteins
JP2023540533A (ja) ヒト血清アルブミンドメインを有する、制約され、条件付きで活性化された結合タンパク質構築物
US20240026011A1 (en) Constrained conditionally activated binding proteins
US12128102B2 (en) Constrained conditionally activated binding proteins
US20230340159A1 (en) Constrained conditionally activated binding proteins
HK40032233A (en) Conditionally activated binding moieties containing fc regions
HK40032913A (en) Constrained conditionally activated binding proteins
EA045012B1 (ru) Ограниченные условно активируемые связывающие белки
EA049569B1 (ru) Ограниченные условно активируемые связывающие белки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20241224